fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Oil Retreats & Yields Invert Leading Markets To Produce Mixed Weekly Results – $FATE $MCD $TELL $TSLA Rise!

By John F. Heerdink, Jr.
Quote of the Day: – “Attitude determines the altitude of life.” – Edwin Louis Cole


The markets overall experienced a “fair to partly cloudy” sort of week, which ended with the indices producing mixed results and leaving many investors guessing as Q1 ended and April Fool’s Day kicked off Q2 on Friday. The major indices results came as follows:  the S&P 500 closed at 4,545.86 (+.1%) for the week and is now only down 4.6% YTD, the Dow 30 ticked lower closing at 34,818.27 (-.1%) and is now only down 4.2% YTD, & the Nasdaq experienced a positive and market leading move as it closed at 14,261.50 (+.7%) and is now down 8.8% YTD.  The small caps also ended moderately higher this week as the Russell 2000 closed at 2,091.11 (+.6%) and is now down 6.9% YTD. The MicroCaps ended surprisingly flat over the last 5-days as the iShares Micro-Cap ETF (IWC) closed at $130.71.

Sector-wise proved to produce about an even battle between the significant down week that the cyclicals experienced i.e. financials, energy, & industrials & the counter and sharply positive weekly move by the more ‘defensive-oriented’ sectors i.e. real estate, utilities, & consumer staples. Biotech stocks, with a solid end of the week surge, also moved well in to positive territory for the week as the Nasdaq Biotechnology ETF (IBB) closed at $133.06, +3.82% over the last 5-days, -12.82% YTD. The NYSE ARCA Biotech Index (^BTK) also closed nicely higher at 5,234.41, +4.12% over the last 5-days. The smaller side of the biotech markets, represented to a degree by the SPDR S&P Biotech ETF (XBI), closed at $93.26, up a more than solid 4.06% over the last 5-days. 

Also, on the positive side, unless you were invested in energy stocks, oil prices gave back last week’s double digit gain and then some to close at $99.54/bbl, -12.6. The downward pressure came after the Biden administration committed to releasing 1M barrels/day for the next 6-months & OPEC+ committed to increasing its output. Hopefully this will also translate to our gas prices going back down to more reasonable levels sooner than later as oil reverts back to the mean. On the downside, the yield curve finally inverted as the 2-yr. treasury yield closed at 2.43%, up 14 basis points, & the 10-yr. yield closed at 2.38%, down 11 basis points.

The macroeconomic schedule also served up yet another group of telling reports this week that left some confused and guessing where the Fed maybe headed with interest rates. On Monday, the Advance report for International Trade in Goods for February confirmed a deficit of $106.6B, a reduction from the January mark. The Advance report for Retail Inventories for February also confirmed a 1.1% rise & the Advance report for Wholesale Inventories for February also moved up by 2.1%. On Tuesday, the Conference Board’s Consumer Confidence Index report confirmed a move up to 107.2 in March, but still off a ~2 points from a year ago. The Job openings report also confirmed a drop to 11.266M in February, while the FHFA Housing Price Index report for February confirmed a 1.6% M/M rise, & the S&P Case-Shiller Home Price Index report for February showed a 19.1% Y/Y jump. Oil prices also backed off as supply worries lessened along with the progress reported during cease fire talks and closed at $104.33, -2%. On Wednesday, the 3rd estimate of Q4 GDP confirmed a lower revision to 6.9%, while the GDP Price Deflator remained at 7.1% The ADP Employment Change report also estimated that 455k jobs were added to private sector payrolls in March & the weekly MBA Mortgage Applications Index dropped 6.8%. On Thursday, the personal income report confirmed a .5% M/M rise in February, while personal spending closed in up .2% & the personal savings rate as a percentage of disposable income rose to 6.3%. The PCE Price Index moved up .6% increasing the Y/Y rate to 6.4. The initial jobless claims report for the week ending March 26 confirmed a rise by 14k to 202k & continuing jobless claims for the week ending March 19 fell by 35k to 1.307M. The Chicago PMI for March also moved up to 62.9. On Friday, the Employment Situation report for March confirmed a less than expected rise in nonfarm and private payrolls, while the average hourly earnings also rose increase &the  average workweek fell. The March ISM Manufacturing Index report showed a drop to 57.1%, but still showing expansion. The Total construction spending report rose by .5% M/M in February.


EV, TECH, CONSUMER, FINANCIALS

Apple (AAPL) closed at $174.32,-.23% over the last 5-days.

On March 31, Apple® announced that Apple Business Essentials™ is now available to all small businesses in the US. The new service brings together device management, 24/7 Apple support, and iCloud® storage into flexible subscription plans. Apple also unveiled new AppleCare+℠ for Business Essentials options that can be added to any plan. Additionally, a two-month free trial will be available to all customers, including those who have been using Apple Business Essentials in beta.
 
On March 30, Apple® announced a $50 million Supplier Employee Development Fund that will expand access to learning opportunities and skills development. The fund also includes new and expanded partnerships with leading rights advocates, universities, and nonprofits to drive Apple’s ongoing work to empower supplier employees and drive improvements in knowledge of and respect for workplace rights across industries. As part of the new $50 million commitment, and building on Apple’s long history in the space, the company is working alongside supply chain partners to amplify worker voice. That includes supporting the worker rights programs created by the International Labour Organization (ILO) for people in the electronics sector, and the work the International Organization for Migration (IOM) is doing to expand rights trainings and scale its industry-leading responsible labor recruitment tools. “We put people first in everything that we do, and we’re proud to announce a new commitment to accelerate our progress and provide even more opportunities for people across our supply chain,” said Sarah Chandler, Apple’s senior director of Environment and Supply Chain Innovation. “Together with rights advocates and education leaders, we are continuing to drive new innovation to support people and the planet.”
 
On March 27, “CODA” became the first film with a predominantly Deaf cast to win Best Picture, star Troy Kotsur is the first Deaf male actor to win an Oscar, Siân Heder wins Best Adapted Screenplay, and Apple became the first streaming service honored with Best Picture at the Academy Awards.

tesla

EV giant Tesla (TSLA) closed at $1084.59, +7.32% over the last 5-days and announced that plans to slit its stack once again.

On March 23, Reuters reported that South Korea’s LG Energy Solution plans to build a battery factory in Arizona to supply to Tesla and other customers. The U.S. factory is expected to produce cylindrical battery cells of different sizes, for customers, including EV makers Lucid and Proterra and Philip Morris, maker of IQOS heated-tobacco sticks. 
 
On March 22, Tesla opened a new plant outside Berlin in Gruenheide. Apparently, Elon Musk followed through again on his promise and proceeded to dance as he delivered the first 30 Model Ys at the festive German occasion. I am glad that I did not see that and I hope that he was not in lederhosen!

Tesla is expected to deliver about 1.4 million vehicles this year. Industry researcher Benchmark Mineral Intelligence expects the company to produce batteries for about 30,000 Model Y vehicles, growing to 484,000 in 2024, according to a previously unpublished forecast provided to Reuters. Tesla’s 4680 lithium-ion batteries – with 46-millimeter diameter and 80-millimeter length – hold about five times the energy of its current smaller 2170 cells. Tesla can use a smaller number of new cells for the same energy and driving range, reducing costs.

On Jan. 26, Tesla reported adjusted Q4 earnings of $2.54 a share with $17.7B in sales, while operating profit clocked in at $2.6B. Telsa’s free cash flow was registered at $2.8B. Each of those figures represents quarterly records for the company. Tesla’s automotive gross profit margins moved up to 29.2% & it produced a record 305,840 vehicles. 

Shares of JPMorgan (JPM) closed at $135.31, -4.66% over the last 5-days. JPMorgan will host a conference call to review first-quarter 2022 financial results on Wednesday, April 13, 2022 at 8:30 a.m. (EDT). The results are scheduled to be released at approximately 7:00 a.m. (EDT). The live audio webcast and presentation slides will be available on www.jpmorganchase.com under Investor Relations, Events & Presentations.

On March 24, Chase, the largest co-brand card issuer in the U.S., and IHG® Hotels & Resorts announced the launch of the new IHG® Rewards Premier Business Mastercard®, with Mastercard as the exclusive payments network, designed to help small business owners turn everyday expenses into meaningful travel rewards. In tandem with this news, Chase and IHG also activated new and enhanced benefits across the IHG® Rewards Traveler and Premier Consumer Mastercard® products.

On March 1, JPMorgan Chase announced five organizations will receive philanthropic capital as part of the firm’s $400 million five-year commitment to improve housing affordability and stability for underserved households, particularly in Black, Hispanic and Latino communities.

Amazon.com, Inc. (NASDAQ: AMZN) $3,295.47, +2.18% over the last 5-days. On March 29, Amazon announced that Amazon Glow is now available for all customers in the U.S., arriving with a growing library of Amazon Kids+ games, visual arts activities, books, and immersive features that add magic to video calls and help build rich family connections. The Glow experience, powered by Amazon Kids+ activities, combines elements of a game system, a children’s library, and an arts-and-crafts center with video chat and an interactive projected space. The result creates a new way for kids and remote loved ones to have fun enjoying the same content at the same time.

On March 24, Amazon launched the Welcome Door program, a new initiative to provide refugee and humanitarian-based immigrant employees with additional resources and support, as well as reimbursement for Employment Authorization Document (EAD) fees.

On March 10, the e-commerce giant announced a 20-for-1 stock split and authorized a $10 billion buyback plan that replaced its previous $5B plan where they had bough back  $2.12B in shares. Amazon will hold its annual shareholder meeting on May 25.

On March 3, Amazon announced that it is further expanding the career advancement opportunities it offers its 750,000 hourly employees in the U.S. by partnering with more than 140 national and local universities to provide fully-funded college tuition. Employees in Texas will have access to education from nine colleges and universities as well as national online education providers, including Southern New Hampshire University, Colorado State University – Global, Western Governors University, and National University.

Shares of Microsoft Corp. (MSFT) closed at 309.42, +1.89% over the last 5-days. On march 31, First Women’s Bank (FWB) announced that Microsoft Corp. and United Airlines are the Bank’s newest Mission Partners. The companies join a growing list of FWB Mission Partners that includes Aon, Wendy’s, Comcast Corp., William Blair and the Western Golf Association, as well as other supporters, including investors Billie Jean King, Fidelity Investments, Bank of America and strategic advisors Sophia Bush and Nia Batts. In addition, FWB is spotlighting some of the small businesses it has financed since its grand opening last fall.

On March 16, Rogers and Microsoft announced a five-year strategic alliance to help enterprise and small and medium business customers accelerate digitization and take full advantage of hybrid work and 5G-enabled solutions. Rogers has selected Microsoft Azure as its strategic cloud for infrastructure and technology workloads and will leverage Azure’s public cloud capabilities to power innovation, unlock new customer experiences and enable employees to collaborate with more agility across the organization.

On March 4, Microsoft announced the completion of its acquisition of Nuance Communications Inc. (Nasdaq: NUAN), a leader in conversational AI and ambient intelligence across industries including healthcare, financial services, retail and telecommunications.

NVIDIA (NVDA) closed $276.12, -3.54% over the past 5-days. On March 22, NVIDIA announced the launch of new NVIDIA Omniverse™ features that make it easier for developers to share assets, sort asset libraries, collaborate and deploy AI to animate characters’ facial expressions in a new game development pipeline. With the NVIDIA Omniverse real-time design collaboration and simulation platform, game developers can use AI- and NVIDIA RTX™-enabled tools, or easily build custom ones, to streamline, accelerate and enhance their development workflows. New features for game developers include updates to Omniverse Audio2Face™, Omniverse Nucleus Cloud and Omniverse DeepSearch, as well as the introduction of Unreal Engine 5 Omniverse Connector.

Cathie Wood’s ARK Innovation ETF (ARKK) closed at $67.54, +4.7% over the last 5-days.

The Technology Select Sector SPDR Fund (XLK) closed at $158.46, +.15% over the last 5-days.

Disney (DIS) closed at $137, -1.54% over the last 5-days. Disney has now pledged to fight Florida’s ‘Don’t Say Gay’ legislation after theMarch 22 60 employee’s walkouts & social media campaigns to protest the company’s response to Florida legislation that would limit classroom discussion of sexual orientation or gender identity.

On Feb 9, Disney reported earnings for its first fiscal quarter ended January 1, 2022 beating the street’s estimates.Diluted earnings per share (EPS) from continuing operations for the quarter increased to $0.63 from $0.02 in the prior-year quarter. Excluding certain items(1), diluted EPS for the quarter increased to $1.06 from $0.32 in the prior-year quarter. “We’ve had a very strong start to the fiscal year, with a significant rise in earnings per share, record revenue and operating income at our domestic parks and resorts, the launch of a new franchise with Encanto, and a significant increase in total subscriptions across our streaming portfolio to 196.4 million, including 11.8 million Disney+ subscribers added in the first quarter,” said Bob Chapek, Chief Executive Officer, The Walt Disney Company. “This marks the final year of The Walt Disney Company’s first century, and performance like this coupled with our unmatched collection of assets and platforms, creative capabilities, and unique place in the culture give me great confidence we will continue to define entertainment for the next 100 years.”

Netflix (NFLX) closed at $373.47, -.1% over the last 5-days. Netflix will post its first quarter 2022 financial results and business outlook on its investor relations website at http://ir.netflix.net on Tuesday, April 19, 2022, at approximately 1:00 p.m. Pacific Time. At that time, the company will issue a brief advisory release via newswire containing a link to the first quarter 2022 financial results and letter to shareholders on its website.

On March 10, Netflix increased its prices for subscribers in the United Kingdom and Ireland. In the UK the price goes to 10.99 pounds  or $14.48 /month,  In Ireland, the basic plan would the standard tier will now cost 14.99 euros or $16.58. On March 2, Netflix announced that it has entered into a combination agreement to acquire Next Games (NXTGMS). Under the terms of the agreement, Netflix will commence a tender offer to acquire all of the issued and outstanding shares of Next Games. Pursuant to the offer, Next Games shareholders will receive €2.1 in cash per share of Next Games, for a total equity value of approximately €65 million. The Board of Directors of Next Games has unanimously decided to recommend that the shareholders accept the tender offer. “Next Games has a seasoned management team, strong track record with mobile games based on entertainment franchises, and solid operational capabilities,” said Michael Verdu, Vice President of Games, Netflix. “We are excited for Next Games to join Netflix as a core studio in a strategic region and key talent market, expanding our internal game studio capabilities. While we’re just getting started in games, I am confident that together with Next Games we will be able to build a portfolio of world class games that will delight our members around the world.”

Shares of McDonald’s (MCD) closed at $249.25, +3.17% over the last 5-days. MCD recently announced the temporary closure of 850 stores in Russia in response to the country’s invasion of Ukraine. However, the company stated that it would continue to pay 62,000 employees in Russia. On Feb. 20, McDonald’s Board of Directors issued the following statement in response to a director notification nomination from Carl Icahn: McDonald’s can confirm that Carl Icahn has nominated Leslie Samuelrich and Maisie Ganzler to stand for election at the 2022 Annual Meeting. There is no shareholder action required at this time. The Board will evaluate the nominees as it would any other candidates proposed to it. The Board utilizes Director Selection Process guidelines to evaluate nominees, which were updated in 2020 to more closely align with the Company’s values and the strategic drivers of its business strategy. Read more.  On Jan. 20, McDonald’s Board of Directors declared a quarterly cash dividend of $1.38 per share of common stock payable on March 15, 2022 to shareholders of record at the close of business on March 1, 2022.

GOLD & SILVER

Gold prices closed at $1,928, -$28/oz. & silver prices closed at $24.81, -$.85/oz. for the week. Hecla Mining (HL) closed at $6.73, -.74% over the last 5-days & First Majestic (AG) closed at $13.58, -2.09% over the last 5-days. 


MEMES REPORT

AMC Entertainment (AMC) closed at $23.30, +15.12% over the last 5-days, and ~39% over the last 10 trading days. On March 15, Hycroft Mining Holding Corporation (Nasdaq: HYMC), a precious metals development company that owns the Hycroft Mine located in the world-class mining region of Northern Nevada, announced a $56 million equity private placement with precious metals investor Eric Sprott and AMC Entertainment Holdings.

GameStop (GME) closed at $165, +8.59% over the last 5-days and ~74% over the last 10-days. GME now plans to split its stock. GME announced that its fourth quarter and full year fiscal 2021 results after the market closes on Thursday, March 17, 2022. Here are a few highlights: Generated net sales of $2.254 billion for the quarter, compared to $2.122 billion in the fourth quarter of 2020 and $2.194 billion in the fourth quarter of 2019, Established new and expanded brand relationships, including with PC gaming companies such as Alienware, Corsair and Lenovo, that contributed to sales growth in the quarter, Grew PowerUp Rewards Pro members by 32% on a year-over-year basis, taking total membership to approximately 5.8 million, & Entered into a partnership with Immutable X that is intended to support the development of GameStop’s NFT marketplace and provide the Company with up to $150 million in IMX tokens upon achievement of certain milestones.

Bed Bath & Beyond Inc. (NASDAQ: BBBY) shares closed at $22.84, +1.11% over the past 5-days. Bed Bath & Beyond announced that it will hold a conference call to discuss its fiscal 2021 fourth quarter financial results on Wednesday, April 13, 2022 at 8:15am EDT. The fiscal 2021 fourth quarter results press release and related materials, for the period ended February 26, 2022, will be issued approximately 45 minutes prior to the start of the conference call.

On March 25, BBBY announced that it has entered into a cooperation agreement with Ryan Cohen and RC Ventures LLC, the beneficial owners of approximately 9.8% of the Company’s outstanding shares. As part of the agreement, three of RC Ventures’ director designees – Marjorie L. Bowen, Shelly C. Lombard, and Ben Rosenzweig – will immediately join Bed Bath & Beyond’s Board of Directors (the “Board”) as new Independent Directors, and they will also stand for election as part of the Company’s slate at the 2022 Annual Meeting of Shareholders (the “Annual Meeting”). The Board will temporarily expand to 14 members before reverting to 11 members following the Annual Meeting. The three new directors collectively bring deep expertise in capital allocation, corporate governance, strategic planning, and transactions.

Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) closed at $1.15, +0.0% over the last 5-days.  On April 1, Seanergy  announced that its Annual Report on Form 20-F for the fiscal year ended December 31, 2021 (the “Annual Report on Form 20-F”) has been filed with U.S. Securities and Exchange Commission. The Annual Report on Form 20-F may also be accessed through the Company’s website, www.seanergymaritime.com, at the “Investor Relations” section under “Financial Reports”.

On March 16, Seanergy announced that it has successfully completed marine biofuel trials in cooperation with one of its major charterers, NYK Line, on one of the Company’s Capesize Vessels. The biofuel is a 0.50% VLSFO blended with a waste-based and ISCC certified FAME component at a 90% – 10% ratio. Advanced real time monitoring instruments and AI have been used to assess the results of the trials.

CRYPTO & BITCOIN

Bitcoin (BTC) closed at $46,364.77, -1.62% over the last 5-days.  

ENERGY

The Energy Select Sector SPDR Fund or ETF (XLE) closed at $77.06, -2.15% over the last 5-days. Chevron (CVX) closed at $164.22, -3.01% over the last 5-days.

Shares of Tellurian Inc. (NYSE American: TELL) closed up +8.56% over the last 5-days. TELL announced on March 28 that it has issued a limited notice to proceed to Bechtel Energy Inc. (Bechtel) under its executed Engineering, Procurement and Construction (EPC) contract to begin construction of phase one of the Driftwood LNG terminal, a liquefied natural gas (LNG) export facility near Lake Charles, Louisiana. President and CEO Octávio Simões said, “Energy security is a leading concern in many countries today and the United States must do our part to supply LNG to the global market as quickly as possible. Beginning construction now allows Tellurian to deliver upon our robust schedule for first LNG in 2026 while we complete the project financing. We are well advanced in Driftwood LNG’s detailed engineering and major equipment orders, and we have completed all the owners’ projects required for us to turn the site over to Bechtel.”


NEXT WEEK

Back to 5 volatile trading sessions next week.

VP WATCHLIST UPDATES

Please review our complete VP Watchlist that includes Apple (AAPL), Disney (DIS), Tesla (TSLA) & a select group of emerging names.  The pages will allow you to learn more and keep up with these companies daily.

For now, see the summaries or five of the emerging companies from the VP Watchlist below:


Shares of INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, closed at $8.37, -6.95% over the last 5-days. The 52-wk range is $6.18 – $30.37.On March 30, INmune Bio announced the Company’s Chief Scientific Officer Dr. Lowdell would be leading a workshop on the role of natural killer (NK) cells in the treatment of solid tumors. The presentation, titled, “Challenges of NK Immunotherapy of Solid Tumors: Potentiation of intra-tumoral NK Function,” is part of the 7th Innate Killer Summit being held in San Diego from March 30 to April 1. The Innate Killer Summit conference is widely viewed as one of the most important meetings in translational NK cell immunotherapy. Dr. Lowdell, CSO of INmune Bio stated, “NK cells are established as an important part of the anti-tumor immune response, but their clinical application has been difficult, especially in solid tumors. This workshop strives to understand why NK cell therapies fail in solid tumors and how we can improve the therapeutic response and practicality of NK therapeutics. Our aim is to make NK cells effective in the fight against cancer so patients will benefit.” Since the last Innate Killer Summit, INmune has treated three patients with INKmune™ and will share these results with the NK community at the conference. The first MDS patient, a 74-year-old man, remains stable 9 months after therapy. Updated results at the lowest dose cohort of INKmune treatment at day 119 show: NO side effects – NO evidence of alloresponse to INKmune™, Evidence of disease control and maintenance of MRD after 3 doses, Improved BM function – No G-CSF / Platelet independent, Improved ECOG score from 2 to 0, Production of tumor killing memory like NK cells., & Persistence of activated NK cells in blood to Day 119 at least. The company also reported that a 21-year-old female with relapsed AML and mixed chimerism after stem cell transplant reestablished 100% donor chimerism after INKmune™ therapy. She remains under close observation as an out-patient more than 6 months after INKmune™ therapy. The third patient, a young man with AML who failed two transplants remains desperately ill. “The Innate Killer Summit is the best place to share our data and discuss our pre-clinical and clinical results with the community of scientists developing NK-based immunotherapies”, added Dr Lowdell.

 
    • On March 25, INMB announced reviews findings from data presented at AD/PD™ 2022 – International Conference on Alzheimer’s and Parkinson’s diseases. The AD/PD™ 2022 International Conference was from March 15-20 in Barcelona, Spain. “The field of AD is changing rapidly as treatments beyond amyloid and tau are explored. Targeting neuroinflammation, the use of biomarkers, and novel clinical trial designs are changing the way drugs are developed for this challenging disease,” said R.J. Tesi, INMB’s CEO. “In my opinion, there are three key observations that put the nine presentations by INmune Bio in perspective. We remain convinced that targeting glial activation with Xpro™ is a smart strategy.”
    • On March 23, eight Form 4’s were filed representing a significant increase in insider buying in INMB’s stock. Please see filings at the direct link at sec.gov
    • On March 15,  INmune Bio announced nine pieces of data, including oral symposia, would be presented at AD/PD™ 2022 – International Conference on Alzheimer’s and Parkinson’s diseases. The AD/PD™ 2022 International Conference is being held from March 15-20 in Barcelona, Spain. Raymond J. Tesi, Ph.D, Chief Executive Officer of INmune Bio, commented, “This is the first time many clinician teams in Europe and UK have been exposed to XPro™ and INmune Bio’s approach to treatment of Alzheimer’s Disease,” said RJ Tesi. “These nine presentations show the versatility of XProTM and the importance of neuroinflammation in the pathogenesis of neurodegenerative disease. The presentations provide a great overview of XPro™ for the treatment of AD, introducing the novel biomarkers INmune is using, and how the results of the Phase I trial provided insight into the design the Phase II trials in mild cognitive impairment and Mild Alzheimer’s.” LEARN MORE HERE. 
    • On March 3, INmune Bio reported its financial results for the year ended December 31, 2021 and provided a business update. INmune Bio highlighted that in December, the Company reported data from the first patient treated with INKmuneTM in the myelodysplastic syndrome (MDS) Phase I clinical trial. More than 100 days after the course of INKmuneTM therapy, 60% of the patient’s NK cells showed the activated, tumor killing memory like NK cells phenotype, a fourfold increase from pre-treatment. The patient’s memory like NK cells killed >70% of NK resistant tumor cells in an in vitro assay. The patient remains well and with an ECOG status of 0, a two-point drop from pre-treatment. Additionally, two patients were treated with INKmuneTM under compassionate use after having failed at least one allogeneic bone marrow transplant. One of the two patients has been discharged home, one remains hospitalized. In all cases, INKmuneTM therapy was well tolerated, safe and was given without any type of pre-medication or cytokine therapy.


RJ Tesi, M.D., Chief Executive Officer of INmune Bio stated, “These patients demonstrate the unique attributes of INKmuneTM therapy in patients with high-risk MDS/AML. INKmuneTM converted the patient’s resting NK cells into cancer killing memory like NK cells. The memory like NK cells killed NK-resistant cancer cells in an in vitro assay. Both these attributes lasted four months, a trait we are calling therapeutic persistence. We are continuing to screen patients for enrollment into the trial and are in process of expanding the number of clinical trial sites.”


    • On Jan. 25, INmune announced that the company has entered into a pre-clinical research collaboration with Chinese University of Hong Kong (CUHK) to evaluate INKmune™ — the company’s pseudokine NK cell priming platform — in nasopharyngeal cancer (NPC), a type of head and neck cancer. The Strategic Partnership Award for Research Collaboration, which was granted by the CUHK Office of Academic Links, is between Prof. Michael Tong at CUHK and Prof. Mark Lowdell at University College London (UCL) and Chief Scientific Officer of INMB. The project provides INMB scientists working at UCL with access to the only three proven NPC cancer cell lines to test the ability of INKmune-primed NK cells to kill NPC tumors.
       
      Prof. Lowdell stated, “Our colleagues at CUHK have been studying NK cell responses to NPC for many years but have not yet translated them into clinical trials. They have shown the need for cytokine activation with IL2 or IL15 to achieve tumor killing. We believe pseudokine activation by INKmune will provide all the relevant NK activating signals of IL2 and IL15 plus a host of other critical NK survival signals and generate memory-like NK cells. We are confident that these INKmune primed cells will kill NPC tumor cells very effectively and we look forward to a mutually beneficial collaboration.”
       
      RJ Tesi, INmune Bio’s Chief Executive Officer stated, “Over 180,000 cases of NPC were diagnosed last year with 85% originating in Asia. Current treatments are quite poor, leading to high mortality rates. History of EBV infection (commonly known as mono) and genetic polymorphisms drive the incidence of the disease. This peer-reviewed grant and international collaboration targeting what has historically been a difficult to treat solid tumor validates the versatility of INKmune. We look forward to translating this work to the clinic in the near future.”
    • On Dec. 1,  INmune Bio announced two poster presentations at the 2021 British Society of Immunology Congress, which was held November 28-December 1, in Edinburgh, UK. Mark Lowdell, PhD, Chief Scientific Officer of INmune Bio, stated, “I’m delighted to have two of our team presenting our latest data on the mechanism of action of INKmune. These are the first comprehensive data showing that INKmune-mediated priming generates NK cells with memory-like phenotype (mlNK). Before this, mlNK cells could only be produced using multiple combinations of cytokines. These are the data which led us to the concept that INKmune is a ‘pseudokine’ that provides multiple signals to NK cells, akin to the multi-cytokine cocktails used by others. We also show that INKmune priming promotes significant proliferation of mlNK cells in vitro. These in vitro data have been replicated in the first patient treated with three, weekly doses of INKmune for high risk MDS. At 119 days post first treatment, 60% of the patient’s NK cells showed the activated, tumor killing phenotype compared to fewer than 15% before INKmune therapy. The patient remains well and with a significantly improved ECOG status.”



  • Shares of InMed Pharmaceuticals, Inc. (NASDAQ: INM), a leading clinical-stage pharmaceutical company developing cannabinoid-based drug candidates for high unmet medical needs and IntegraSyn, a proprietary and cost effective manufacturing approach for synthesized rare cannabinoids, closed at $.9256, -17.36% over the last 5-days.  Please visit the INM page at our website to learn more and check out the videos section too. The 52-wk range is $.652 – $3.99
    • On March 17, InMed announced that its Chief Financial Officer, Mr. Bruce Colwill, will be retiring and will be stepping down from his position at the Company effective March 31, 2022. Mr. Colwill will continue to serve as an advisor through June 30, 2022 to facilitate a smooth transition. Ms. Brenda Edwards has been appointed as Interim Chief Financial Officer of the Company effective April 1, 2022. The Company has initiated a search for a full time replacement. Ms. Edwards brings over 35 years experience to InMed including over 20 years as a Chief Financial Officer of both private and public companies. Her experience includes merger and acquisitions, financings, managing high growth situations and financial reporting. She is a member of both the American Institute of CPAs and the Chartered Professional Accountants of Canada.
    • On  Feb. 15, Inmed announced the appointment of Gerard (Jerry) P. Griffin III as Vice President of Sales and Marketing at BayMedica, a wholly owned subsidiary of InMed. Mr. Griffin will oversee the commercialization of BayMedica’s health and wellness business including the existing products and the launch of new rare cannabinoid products. Mr. Griffin has a wealth of experience across various markets and with numerous cannabinoid products, and a proven track record as a seasoned sales executive. He has held several senior positions at both privately and publicly held companies including Fortune 500 companies. Most recently, Mr. Griffin was the Vice President of Sales and Business Development at Creo Ingredients, a biotechnology-based ingredient company that produces rare cannabinoids. Prior to Creo, he was the President of a successful wellness company, overseeing all aspects of a business that develops and distributes cannabinoid-based products. With his extensive hands-on experience in the rapidly expanding cannabinoid industry, he brings significant real-world knowledge across the entire value chain to the Company.

    • On Feb. 14, InMed announced financial results for the second quarter of fiscal year 2022 which ended December 31, 2021. They highlighted that they completed the acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sector, they strengthened IP with patent filing for use of rare cannabinoids for the treatment of neurodegenerative diseases, they initiated the commercial rollout of an additional rare cannabinoid, CBT- first of several rare cannabinoid launches planned for the first half of 2022, & they advanced the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseases. READ THE BALANCE OF THE RELEASE.

    • On Jan. 19, InMed announced that it has launched B2B sales of the rare cannabinoid cannabicitran (CBT) into the health and wellness sector. CBT is the first of several new product launches planned for the first half of 2022. InMed’s subsidiary, BayMedica, has received initial purchase orders and has commenced commercial sales of the ultra-rare cannabinoid CBT. CBT is the second rare cannabinoid to be launched by BayMedica, which also sells CBC wholesale as a raw ingredient to the health and wellness sector. Additionally, commercial scale production of cannabidivarin (CBDV) is underway, with tetrahydrocannabivarin (THCV) production scheduled to follow shortly thereafter. The Company expects to produce over 100kg of CBDV and THCV in the coming months to meet anticipated initial demand. Shane Johnson, SVP and General Manager of BayMedica stated, “We are delivering on our objective to launch additional rare cannabinoids in early 2022 in response to inbound demand. By midyear, we expect to have at least four rare cannabinoids available for the health and wellness markets, positioning us as a leading large scale supplier of high quality rare cannabinoids in these sectors. The launch of CBT further demonstrates our ability to produce rare cannabinoids at commercial scale, an achievement that very few companies have been able to accomplish. We are pleased with initial demand and we expect to grow sales over the coming quarters as we continue to expand our product portfolio of rare cannabinoids.” This emerging market is expected to grow significantly due to the increasing awareness of the potential benefits of cannabinoid-based products. According to the December 2021 Grand View Research report, the retail market for rare cannabinoids is expected to reach US$26 billion by 2028 with a forecasted compounded annual growth rate (CAGR) of >20% during the same period. With the availability of these rare cannabinoids at commercial scale, product manufacturers and consumer brands now have the ability to deliver differentiated products, including augmenting existing CBD-based products, to consumers in the health and wellness marketplace.
    • On Jan. 6, our sister organization, Tribe Public, held a FREE Webinar Presentation and Q&A Event with InMed Pharmaceuticals (NASDAQ: INM) titled “Addressing The Increasing Demand For Rare Cannabinoids” with Eric A. Adams, MIBS, CEO & President of InMed Pharmaceuticals (NASDAQ: INM) SVP, General Manager of BayMedica Shane Johnson, MD & VP, Commercial Operations Chris Meiering, PhD. The event was very interesting and informative, well attended, and now the event video is now published at the Tribe Public YouTube Channel. You may view it now by clicking here

    • On Jan. 5th, InMed issued its Annual Letter to Shareholders from President and CEO Eric A. Adams which stated, “Building on a very strong 2021, we are looking forward to 2022 with the continued advancement of our pharmaceutical drug development programs and, with our acquisition of BayMedica, transitioning to becoming a leading B2B supplier of rare cannabinoids to the consumer health and wellness sector. I’m very excited to provide updates on our progress as we begin to commercialize new products and explore an array of rare cannabinoids for their potential therapeutic applications.” Click here to read the letter
    • On Dec. 20, InMed announced that a peer-reviewed scientific article entitled “Cannabinol Modulates Neuroprotection and Intraocular Pressure: A Potential Multi-Target Therapeutic Intervention for Glaucoma”, has been published in Biochimica et Biophysical Acta (BBA – Molecular Basis of Disease), a leading international journal focused on biochemistry and molecular genetics of disease processes and models of human disease in the area of aging, cancer, metabolic-, neurological-, and immunological-based diseases. The peer-reviewed article highlights research evaluating the use of cannabinol, or CBN, as a potential treatment option for glaucoma. Several studies were conducted to evaluate the survival of retinal ganglion cells, modulation of intraocular pressure and its effects on extracellular matrix proteins using in vitro and in vivo glaucoma models. These studies resulted in two key findings: first, CBN may promote neuroprotection of cells in the retina that are responsible for vision; and second, CBN may normalize intraocular pressure by attenuating changes in the extracellular matrix proteins. The article also reports on the comparison of CBN with other cannabinoids, including cannabidiol (CBD) and tetrahydrocannabinol (THC), with results indicating that CBN has a stronger effect and broader neuroprotective therapeutic range. These observations elucidate the therapeutic potential for CBN in the treatment of glaucoma.
    • On Nov. 29, InMed Pharmaceuticals (NASDAQ: INM) received a BUY Recommendation from Raghuram Selvaraju, Ph.D. a sell side analyst at H.C. Wainwright & CO. with a Price Target of $6. His report is titled “Charging After Pharmaceutical-Grade Cannabinoids; Initiating at Buy and $6 PT”.  
    • On November 10, InMed announced their financial results for the first quarter of fiscal year 2022 which ended September 30, 2021. “The first quarter of fiscal 2022 saw positive momentum across all of our programs,” says Eric A. Adams, InMed President & CEO. “With the completion of the BayMedica Inc. (“BayMedica”) acquisition, our integrated teams are working together to identify rare cannabinoids in BayMedica’s pipeline for commercialization in the consumer health and wellness industry. For the duration of fiscal year 2022, we will be focused on growing revenues through the launch of these selected rare cannabinoids, in addition to expanding sales of BayMedica’s Prodiol® CBC (cannabichromene) and progressing our existing programs.”
    • On October 13, InMed announced that they have completed the previously announced acquisition of BayMedica Inc. (“BayMedica”), a private company based in the US specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector. Eric A. Adams, President and Chief Executive Officer of InMed, stated, “We are delighted to close this acquisition and welcome everyone at BayMedica to the InMed team. In the next several weeks, we will focus on corporate integration, exploring our combined manufacturing know-how and looking to accelerate revenue growth. BayMedica brings significant expertise and will help strengthen our pharmaceutical drug development efforts as well as position the Company to become a global leader in the manufacturing of rare cannabinoids.”
    • On September 30, INmed announced that it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”). This marks the first time cannabinol has advanced to a Phase 2 Clinical trial to be studied as a therapeutic option to treat a disease. This study will be taking place at eleven sites across seven countries including Austria, Germany, Greece, France, Italy, Israel and Serbia. Clinical Trial Applications (“CTAs”) have been filed in all participating countries with regulatory authority and ethics committee approvals currently in place in four countries (Austria, France, Greece, Israel). The first site initiation visit was completed at a clinical site in Austria, where screening for eligible patients will begin shortly. “The start of this Phase 2 clinical trial represents a very important step forward to test the efficacy of INM-755 (cannabinol) cream in treating epidermolysis bullosa, a disease that has very few treatment options,” stated Alexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs at InMed. “Based on our earlier studies, we are hopeful that our cannabinol cream will prove to be a safe and effective treatment for people living with this severe genetic skin disease.”
    • On July 9th, Roth Capital Partners analyst Scott Henry, CFA issued an update report with. BUY Rating titled, “INM: Favorable Take on BayMedica LOI” that includes a $11.50 12-Month Price Target.


  • Shares of Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $41.32, +8.74% over the last 5-days. 
    • On Feb. 28, Fate Therapeutics reported business highlights and financial results for the fourth quarter and full year ended December 31, 2021. Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics, “We have begun 2022 with strong clinical and regulatory momentum driving our off-the-shelf, iPSC-derived NK cell programs in relapsed / refractory lymphoma, and look forward to working with the FDA under the Regenerative Medicine Advanced Therapy designation to accelerate therapeutic development in areas of significant unmet need, such as patients who have progressed following autologous CAR T-cell therapy, and to bringing transformative cell therapies to patients in the community setting including as part of early-line treatment. We maintain a strong financial position and are poised in 2022 to achieve key clinical milestones and data read-outs across our wholly-owned disease franchises, to extend our leadership in the manufacture and CMC of iPSC-derived cell therapies with the launch of our second cGMP manufacturing facility, and to bring new multiplexed-engineered NK and T-cell product candidates to patients.”
    • On Jan. 10, Fate announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate. FT536 is derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with four functional elements, including a novel CAR that uniquely targets the α3 domain of the major histocompatibility complex (MHC) class I related proteins A (MICA) and B (MICB). MICA and MICB are stress proteins that are expressed at high levels on many solid tumors. The Company plans to initiate clinical investigation of FT536 as a monotherapy and in combination with tumor-targeting monoclonal antibody therapy for the treatment of multiple solid tumor indications.
    • On Monday, Dec. 13, Fate showcased positive interim Phase 1 data from the Company’s FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. FT596 is the Company’s off-the-shelf, multi-antigen targeted, iPSC-derived natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with three anti-tumor functional modalities: a proprietary chimeric antigen receptor (CAR) optimized for NK cell biology that targets B-cell antigen CD19; a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor that has been modified to prevent its down-regulation and to enhance its binding to tumor-targeting antibodies; and an IL-15 receptor fusion (IL-15RF) that augments NK cell activity. “The interim dose-escalation clinical data from our FT596 program in relapsed / refractory B-cell lymphoma demonstrate that off-the-shelf, iPSC-derived CAR NK cells can bring substantial therapeutic benefit to heavily pre-treated patients in urgent need of therapy, with high response rates and meaningful duration of responses,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. “We are particularly pleased with the therapeutic profile that has emerged with FT596 in combination with rituximab, where over half of the patients treated with a single dose of FT596 at higher dose levels achieved a complete response with a favorable safety profile that is clearly differentiated from CAR T-cell therapy. We look forward to assessing a two-dose treatment schedule for FT596 to further define its potential best-in-class therapeutic profile and ability to reach more patients, including those earlier in care.”

    • On Nov 4, FATE reported business highlights and financial results for the third quarter ended September 30, 2021. Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics stated, “The interim Phase 1 data from our FT516 and FT596 programs in relapsed / refractory lymphoma demonstrate that our off-the-shelf, iPSC-derived NK cell product candidates have the potential to deliver substantial therapeutic benefit for patients along with a differentiated safety profile that supports outpatient treatment. We look forward to sharing additional clinical data from both of these programs at the American Society of Hematology Annual Meeting in December. We also continue to be pleased with the clinical advancement of our multiplexed-engineered, iPSC-derived NK cell pipeline, where we have now successfully treated the first patients with FT516 in disease-specific expansion cohorts for lymphoma and with FT538 in combination with daratumumab for multiple myeloma. Additionally, we have successfully completed GMP manufacture and release of FT576, our multi-antigen targeted, CAR BCMA product candidate for multiple myeloma, and have initiated enrollment in our Phase 1 study.”
    • On Oct. 1, Fate announced that one oral and four poster presentations for the Company’s induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021. The oral presentation will highlight preclinical data for FT536, the Company’s off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate that uniquely targets the α3 domain of the MHC class I related proteins A (MICA) and B (MICB). In a recent publication in Cancer Immunology Research (DOI: 10.1158/2326-6066.CIR-19-0483), Kai W. Wucherpfennig, M.D., Ph.D., Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and co-leader of the Cancer Immunology Program at Dana-Farber / Harvard Cancer Center, demonstrated that cancers with loss of MHC Class I expression can be effectively targeted with MICA/B α3 domain-specific antibodies to restore NK cell-mediated immunity against solid tumors. The FT536 program is supported by an exclusive license from the Dana-Farber Cancer Institute to intellectual property covering novel antibody fragments binding MICA/B for iPSC-derived cellular therapeutics. The Company expects to submit an Investigational New Drug (IND) application for FT536 in the fourth quarter of 2021 for the treatment of advanced solid tumors, including in combination with monoclonal antibody therapy.
    • On September 15, Fate Therapeutics announced the publication of preclinical data demonstrating that its off-the-shelf, multiplexed-engineered, iPSC-derived NK cell product candidate FT538 exhibits significantly enhanced serial killing and functional persistence compared to peripheral blood NK cells. The superior anti-tumor activity of FT538 was attributable to its novel engineered components, including the knockout of CD38 and the expression of IL-15/IL-15R fusion protein, which were shown to improve metabolic fitness, increase resistance to oxidative stress, and induce transcription of proteins that control NK cell activation and effector function. The data were published in Cell Stem Cell in an online article entitled “Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy”.


  • Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at closed at $1.24, -13.89% over the last 5-days. 
  •  
    • On March 8, Atossa announced that the U.S. Patent and Trademark office has issued a new patent further strengthening Atossa’s intellectual property in its proprietary therapy Endoxifen, which is under development for breast cancer and other breast conditions. U.S. Patent No. 11,261,151 (the ‘151 Patent) is titled “Methods for Making and Using Endoxifen” and is directed to compositions of storage-stable Endoxifen and methods of treating hormone-dependent breast disorders using the storage-stable Endoxifen. “We are very pleased with the scope and breadth of this new key patent,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. “Patents covering the composition of matter of new therapies are critical to protect markets from generic competition. The ‘151 Patent,’ with its estimated expiration in 2038, strengthens our intellectual property estate and should create long-term stockholder value.”Atossa is developing its proprietary Endoxifen in two clinical settings: one to reduce tumor cell activity in breast cancer patients in the neoadjuvant setting, meaning prior to surgery; and another to reduce dense breast tissue in women. A Phase 2 study is currently underway in women with measurable breast density and Atossa plans to submit a request (IND) to the FDA to open other Phase 2 in the neoadjuvant setting in the next quarter. Atossa’s neoadjuvant program is focused on breast cancers that are classified as estrogen receptor positive (ER+). Although there are numerous neoadjuvant treatments for breast cancers that are not ER+, there are few neoadjuvant treatments for ER+ breast cancer which comprises about 78% of all breast cancers. We believe there is a compelling need for therapy with our Endoxifen in this setting. An estimated ten million women in the U.S. have mammographic breast density, or MBD, for which there is no FDA-approved treatment. MBD is an emerging public health issue and studies conducted by others have shown that MBD increases the risk of developing breast cancer and that reducing MBD can reduce the incidence of breast cancer. The American Cancer Society estimates that in the U.S. in 2022, 287,850 women will be diagnosed with breast cancer, 47,550 of which will be under the age of 50 and 43,250 of which will die from the disease.
    • On Feb. 28, Atossa announced their financial results for the fiscal quarter and fiscal year ended December 31, 2021 and provides an update on recent company developments. Dr. Steven Quay, Atossa’s President and Chief Executive Officer stated, “We continue to make significant progress on our Endoxifen and COVID-19 programs, with the continuation of enrollment of the Australian trial for AT-H201, as well as enrollment in our Swedish Endoxifen Phase 2 trial. We look forward to moving into the next milestones during 2022, and to providing updates on these developing therapies for urgent unmet patient needs. Further, our strong balance sheet will continue to facilitate our development plans as we not only execute on these trials but also explore additional options that could create significant shareholder value.” READ The Balance of the story
    • On Jan. 27, Atossa issued the annual letter from President and CEO Dr. Steven C. Quay to Atossa stockholders.  The letter Bega as follows: “The last two years have changed the face of public health and uncovered the urgency to develop products not only to prevent widely spread infectious diseases, but to treat them with the same level of focus and dedication applied to prevention. Despite the launch of highly efficacious vaccines during 2021, the toll that COVID-19 was taking on public health was not reduced. The rise of the Omicron variant toward the end of the year, and emerging long-term impact of long COVID, remain an important public health priority, and one that Atossa is dedicated to addressing. A key feature of the original SARS-CoV-2 virus, and that is retained in both the Delta and Omicron variants, is the furin cleavage site found on the Spike protein which facilitates viral infection. Our COVID-19 programs under development are designed to interact with this cleavage site so they are expected to be effective against both current and future COVID-19 variants that continue to contain a furin cleavage site. In the meantime, we are also very excited about the ongoing development of our breast health programs with our proprietary drug Endoxifen, with one Phase 2 study underway and another expected to commence in the next quarter. We raised over $110 million in capital in 2021 and we are well positioned to execute on our programs in 2022.” Click here to read the balance of the letter now.
    • On Jan. 18, Atossa announced it is advancing to enroll participants in Part B of its Phase 1/2a clinical study of AT-H201 in Australia, consisting of multiple ascending dose cohorts in healthy participants. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely-ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease. Part A of the study, which consisted of a single ascending dose group of 4 cohorts of healthy participants, has now been completed. The Australian Human Research Ethics Committee has reviewed the safety data from Part A and has approved the study to proceed to Part B. “The results of the first part of the study were extremely encouraging and the ethics committee concluded we may now proceed to enroll the next group of participants,” said Steven Quay, M.D., Ph.D., Atossa’s CEO and President. “A record number of hospitalizations driven by the Omicron variant is producing a crisis at many healthcare facilities. Additional therapies to combat COVID-19 are desperately needed.” The Phase 1/2a placebo-controlled study will enroll a total of 60 healthy participants and moderately-ill hospitalized COVID-19 patients. The study has 4 parts: Part A – a single ascending dose part, Part B – a multiple ascending dose part, Part C – a combination part in healthy individuals, and Part D a combination in COVID-19 infected patients. The study is being conducted by Avance Clinical Pty Ltd., a leading Australian clinical research organization. AT-H201 is a proprietary combination of two drugs previously approved by the FDA to treat other diseases and by other administration routes. AT-H201 is intended to be inhaled via a nebulizer to improve compromised lung function for moderate to severely ill, hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease. In May 2020, we completed in vitro testing of AT-H201 which showed that the components of AT-H201 inhibit SARS-CoV-2 infectivity of VERO cells, which is a standard cell type being used to study infectivity of the coronavirus. The Phase 1/2a study in Australia and other clinical studies must be successfully completed and regulatory approvals must be obtained before AT-H201 may be commercialized. No assurance can be given than studies will be successful or that regulatory approvals will be obtained.
    • On Dec. 22, Atossa announced that it has initiated enrollment of its Phase 2 clinical study of oral Z-Endoxifen in Sweden. Participants in the study will be premenopausal women with elevated mammographic breast density, which is an emerging public health issue affecting more than 10 million women in the United States and many more worldwide. “This is an extremely important milestone as it marks the next phase of developing our proprietary Z-Endoxifen,” said Steven Quay, M.D., Ph.D., Atossa’s Chairman and CEO. “This study will help determine the relationship between daily doses of Endoxifen and reduction in breast density and will help us further assess safety and tolerability. We look forward to providing progress updates as they become available.” Physician-Scientist and CEO of Atossa, Steven Quay, MD, PhD, recently published an e-print on his research into a new coronavirus, named BANAL-236, reported by the Institut Pasteur in September 2021. At the time, BANAL-236 was the first bat coronavirus with high homology to SARS-CoV-2 that could directly infect human cells using the same receptor that SARS-CoV-2 uses. The new research reports that BANAL-236 has evolved the ability to infect human cells by an unknown mechanism that violates over 40 years of coronavirus research. The COVID-19 e-print is available here and has also been submitted to Nature. “When I read the paper from the Institut Pasteur and looked at the virus, I immediately assumed there was an error in either the way the sequence was assembled or a mix up in the lab with another virus to explain the infectivity,” Quay said. “I contacted the Institut Pasteur with my findings and was deeply disturbed to learn that there was not, in fact, some simple mistake had occurred to explain things. I now knew we were in uncharted waters with a virus that is missing eight key elements that have been shown, over 40 years of research, to be required for growth.”
    • Recently, Physician-Scientist and CEO of Atossa, Steven Quay, MD, PhD, published an e-print on his research into a new coronavirus, named BANAL-236, reported by the Institut Pasteur in September 2021. At the time, BANAL-236 was the first bat coronavirus with high homology to SARS-CoV-2 that could directly infect human cells using the same receptor that SARS-CoV-2 uses. The new research reports that BANAL-236 has evolved the ability to infect human cells by an unknown mechanism that violates over 40 years of coronavirus research. The COVID-19 e-print is available here and has also been submitted to Nature. “When I read the paper from the Institut Pasteur and looked at the virus, I immediately assumed there was an error in either the way the sequence was assembled or a mix up in the lab with another virus to explain the infectivity,” Quay said. “I contacted the Institut Pasteur with my findings and was deeply disturbed to learn that there was not, in fact, some simple mistake had occurred to explain things. I now knew we were in uncharted waters with a virus that is missing eight key elements that have been shown, over 40 years of research, to be required for growth.”
    • On Dec. 6, Atossa announced that it has completed a pre-investigational new drug (PIND) meeting with the FDA. The purpose of the meeting was to obtain input from the FDA on pre-clinical, clinical, manufacturing and regulatory matters in the U.S. for Atossa’s proprietary Z-endoxifen to treat breast cancer in the neoadjuvant (prior to surgery) setting. “Holding a PIND meeting is a critical milestone in the regulatory pathway,” said Dr. Heather Fraser, Atossa’s VP Clinical, Regulatory and CMC. “The feedback we received will be very helpful in preparing our request to the FDA to open an IND for a multi-center Phase 2 study to further advance our Z-endoxifen in the neoadjuvant setting. We plan to focus our development on pre-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer for whom the current treatment options typically include drugs that suppress ovarian function and essentially force the patient into menopause. We look forward to opening an IND in the second quarter of 2022 and then commencing a Phase 2 study in this setting. Despite the uncertainties and challenges created by the worldwide, COVID-19 pandemic in 2021, it is gratifying to be able to announce this major step forward for our proprietary Z-endoxifen program development in the U.S., the largest market for pharmaceuticals for the treatment of breast cancer,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. “The guidance from this meeting with the FDA, together with the ongoing non-clinical studies with Z-endoxifen and the initiation of a technology transfer process to establish a commercial cGMP manufacturing supplier to support the further drug development and ultimate commercial launch of Z-endoxifen, will put Atossa in an excellent position to continue the development of Z-endoxifen in 2022.”
      Based in part on the feedback received from the FDA and subject to its approval, Atossa’s current plan, is to continue developing Z-endoxifen for the treatment of pre-menopausal women with ER+/HER2- breast cancer in the neoadjuvant setting. Atossa plans to apply to the FDA for an IND to conduct a Phase 2 study in the U.S. to compare Z-endoxifen to standard of care, which is typically ovarian functional suppression along with either an aromatase inhibitor or tamoxifen. Atossa also plans to conduct a pharmacokinetic run-in study as a part of the Phase 2 study to further define potential dose levels.

    • On Nov. 30,  Atossa Therapeutics’ CEO, Dr. Steven Quay, M.D., Ph.D., and Kyle Guse, GC & CFO presented at our sister organization Tribe Public’s FREE Webinar Presentation and Q&A Event. During this complimentary event, Atossa management addressed Q&A from the Tribe focused on Atossa’s research programs and future development. You can watch the event video titled “A Town Hall Q&A Event With Atossa Therapeutics Management Team” at the Tribe Public YouTube Channel by clicking here
  •  


  • Shares INVO Bioscience (NASDAQ: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, closed at $2.48, -4.25% over the last 5-days.
 
  • Regained full U.S. commercialization rights to sell its INVOcell® solution directly into existing in vitro fertilization (IVF) clinics, to expand the number of U.S. INVO Centers free of any limitations, and to pursue its market expansion strategy focused on increasing access to care and democratizing fertility care for the underserved patient population.
  • Opened three INVO Center’s in 2021, including Birmingham, Alabama, Atlanta, Georgia, and Monterrey, Mexico with another clinic scheduled to open in the San Francisco area. The Company recently identified Tampa, Florida as the location of the next INVO Center.
  • Entered into an agreement with Ovo in Spain to expand INVOcell® commercialization in all four of their Ovoclinics, establish a European center of excellence and training site for INVOcell® and the IVC procedure, and leverage Ovobank’s fertility clinic relationships across Europe.
  • Completed the acquisition of a Canadian-based entity, originally formed to offer INVOcell®, to advance distribution efforts in Canada, where the product is already approved by Health Canada and cleared for importing.
  • Obtained regulatory approval to commercialize INVOcell® in Thailand and Nigeria.
  • Presented four poster abstracts discussing INVOcell® at the 77th Scientific Congress & Expo of the American Society for Reproductive Medicine held in Baltimore, Maryland in October 2021.
  • Revenue was $4.2 million for the year ended December 31, 2021, including $2.9 million due to the accelerated recognition of deferred revenue from the Ferring license, and compared to $1.0 million for the previous year.
  • Adjusted EBITDA for 2021 was $(2.8) million, which included a $0.7 million loss attributable to the Company’s joint ventures, compared to $(3.7) million in the prior year (see Adjusted EBITDA Table).

Steve Shum, CEO of INVO stated, “2021 was an exciting year for INVO as we opened our first INVO Center clinics. Our INVO Center model represents a strategy aimed at expanding adoption of INVOcell® and allowing us to capture a significantly larger percentage of the per-cycle IVC procedure revenue it enables. The INVO Centers are designed to offer attractive economics for our shareholders, medical practitioner partners and patients, and we believe are key to our efforts to address the fertility industry’s biggest challenges of cost and capacity. In addition to our announced plans to open additional centers in the San Francisco Bay Area and Tampa, Florida, we are evaluating over 20 additional US locations which represent attractive opportunities to open new INVO Centers. We also are in discussions for similar ventures across the globe. On the distribution side of our business, during the first quarter of 2022, we began selling directly to existing IVF fertility clinics in the U.S., after regaining full domestic commercialization rights to the INVOcell® upon termination of our prior agreements with Ferring. We are also seeing increased distribution activity from some of our partners in Europe and Africa. We are enthusiastic about our multi-channel strategy of supporting, servicing, and expanding across existing IVF clinic networks and building new, dedicated INVO Centers. We expect this strategy to drive increased market awareness and utilization of our revolutionary technology, and provide an affordable and equally effective fertility treatment alternative to the large, underserved patient population.”

 
    • INVO Bioscience exhibited at the INVOcell solution at the 2022 Pacific Coast Reproductive Society (PCRS) Annual Meeting, taking place March 23-27 at the Renaissance Esmeralda Resort & Spa in Indian Wells, CA. Chris Myer, INVO’s Senior VP, Business Development, Americas, and Bojan (Bo) Mitrovic, PhD, INVO’s Director, Sales, US will both be available in Booth #314 discussing INVOcell with the broader Assisted Reproductive Technology (ART) physician community.
      Steve Shum, CEO of INVO Bioscience, commented, “A key component to our go forward commercialization strategy is to synchronize and take an expanded, more comprehensive and direct approach toward our U.S. efforts. PCRS provides us an opportunity to easily connect with a number of U.S. IVF clinics that have already trained on the INVOcell device and the IVC treatment process, as well as introduce our solution to additional clinic operators interested in expanding their treatment options and overall capacity by introducing INVOcell to patients.” Pacific Coast Reproductive Society is a multidisciplinary medical specialty society providing Continuing Medical Education (CME) to physicians and allied healthcare professionals. The PCRS Annual Meeting provides an outstanding forum for the exchange of information and the advancement of the ideologies of reproductive medicine in a relaxed and collegial setting. Session topics have been carefully selected to bring you the highest quality, innovative CME, designed and presented by thought leaders in reproductive medicine.
  •  


  • Shares of NeuBase Therapeutics (NASDAQ: NBSE), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, closed at $1.81, -9.73% over the last 5-days. 
    • On March 16 and March 17, newly appointed Neubase CFO purchased a 10,000 shares of NBSE stock each day for a total of 20,000 shares at $1.62/share and $1.74/share respectively. Here’s the Form 4 filing at the SEC
    • On March 13, Neubase announced new preclinical data for its lead development candidate, NT-0231.F, to treat myotonic dystrophy type 1 (DM1). These data are being presented in poster and oral presentations at the 2022 MDA Clinical & Scientific Conference, which is taking place virtually and in-person in Nashville, Tennessee from March 13-16, 2022. These data was presented at the RNA Leaders World Congress in Basel on March 17th. 
       
      Sandra Rojas-Caro, M.D., Chief Medical Officer of NeuBase, said, “DM1 is a significant unmet medical need characterized by myotonia, muscle weakness and wasting, and cognitive impairments. We are excited to present new preclinical data for our lead candidate, NT-0231.F, to support our differentiated approach for DM1. Systemic administration of NT-0231.F achieves clinically relevant molecular and functional rescue in the muscle in the HSALR model, which reproduces many components of the disease. Initial pharmacokinetic data supports a whole-body solution to the disease, and additional preclinical work is in progress to assess biodistribution in key tissues. These data are an important milestone in our DM1 development program and support our pursuit of a best-in-class therapeutic profile for the disease.”
       
      A single intramuscular dose confirmed that NT-0231.F is pharmacologically active in the muscle and drives molecular and functional rescue in the HSALR model, including splice rescue, nuclear aggregate resolution, and myotonia (delayed muscle relaxation after contraction) reversal. A single intravenous (IV) dose of NT-0231.F or multiple subcutaneous (SC) doses over a 28-day period broadly rescued splicing, including the chloride channel (Clcn1) transcript, and reversed myotonia in the model. A single IV dose of NT-0231.F provides initial splice rescue at around two weeks, with significant splice rescue around three weeks. Myotonia reversal was achieved at around four weeks, with effects enduring to at least six weeks, the longest time point tested so far. A time course of multiple SC doses across increasing concentrations of NT-0231.F was also investigated and showed splice rescue and myotonia reversal in a dose-responsive manner, illustrating feasibility of the differentiated and patient-friendly SC route. In pharmacokinetic studies of NT-0231.F in wild-type BALB/C mice, a single IV or SC dose showed high volume of distribution, suggesting wide tissue distribution. 
       
      Dietrich A. Stephan, Ph.D., Founder, Chief Executive Officer, and Chairman of NeuBase, said, “We now have preclinical data in the gold-standard animal model for our development candidate demonstrating robust reversal of myotonia, as measured by muscle relaxation in these studies. We believe we are the only company that has shown improved muscle relaxation after systemic routes of administration. The HSALR model is also a high bar for human disease in that it contains at least 10x more mutant gene CUG- repeat targets than patients, giving us further conviction in the robustness of our approach. Not only does this data support the further advancement of our lead program in DM1 and keep us on track for submitting an Investigational New Drug application to the U.S. Food and Drug Administration in 4Q CY2022, it also validates that we can utilize our PATrOLTM platform to design novel genetic medicines that target and rescue many other gene dysfunctions, with the potential for clinically impactful outcomes in both rare and common diseases.”
    • On Feb. 28,  Neubase announced that new preclinical data from its myotonic dystrophy type 1 (DM1) program will be featured in presentations at the 2022 MDA Clinical & Scientific Conference. MDA 2022 will be taking place virtually and in-person in Nashville, Tennessee, from March 13-16, 2022, and the abstracts will be available on the meeting website. Expanding upon initial data presented in June 2021, the presentations will include new data of a PATrOL™-enabled investigational genetic therapy for DM1. NeuBase will present molecular and functional pharmacological activity of its DM1 investigational genetic therapy in the HSALR mouse model following single and repeated subcutaneous, intravenous, and intramuscular administration. The HSALR model carry the long repeat (LR) length of the DMPK repeat expansion and recapitulates many aspects of the clinical presentation of DM1. Additional pharmacokinetic data will be presented of NeuBase’s DM1 investigational genetic therapy in wild-type mice demonstrating distribution and pharmacologic activity throughout the body, including the brain and muscle, following systemic administration. Patients with DM1 suffer from cognitive deficits and muscle pathology caused by a trinucleotide expansion in the DMPK gene. NeuBase’s DM1 investigational genetic therapy targets DMPK pre-mRNA with a novel peptide-nucleic acid (PNA) pharmacophore and is designed to selectively engage with the toxic RNA hairpin structure and release the splicing proteins to restore RNA splicing and downstream protein production. The PNA pharmacophore is conjugated to NeuBase’s novel delivery technology that is designed for broad distribution, including into the deep brain, with the potential for a whole body, disease-modifying solution for DM1.
    • On Feb. 10, NeuBase reported its financial results for the three-month period ended December 31, 2021, and other recent developments. Dietrich A. Stephan, Ph.D., Founder, Chief Executive Officer, and Chairman of NeuBase stated,  “We are making significant progress in advancing the IND-enabling studies for the development candidate for our myotonic dystrophy type 1 (DM1) program, and we expect to file an IND with the FDA in Q4 CY2022. These studies are on track for data readouts to occur throughout CY2022, with the first presentation of rodent pharmacokinetic and bioavailability data to occur at an upcoming scientific meeting. We expect these data to illustrate the differentiated potential for our candidate to be a whole-body solution to treat DM1 and the unique ability of our delivery shuttle for distribution into the brain. The ability to cross the blood brain barrier and reach the deep brain is also especially relevant for our Huntington’s disease program, where we are planning to initiate scale-up and toxicology activities this year. In addition, I’m especially excited to have welcomed Todd to the executive team as Chief Financial Officer. The team and science are strong, and I believe we are at a pivotal moment for NeuBase as we are building a robust data package that is expected to support bringing our first candidate into the clinic for DM1, validate our genetic medicine technology platform to efficiently deliver genetic medicines with broad tissue distribution, including into the deep brain, and to precisely engage genetic mutations in a manner that is well-tolerated with the potential for sustained efficacy.” READ THE BALANCE OF THE RELEASE HERE. 
 

Dietrich A. Stephan, Ph.D, CEO, & Founder of NeuBase Therapeutics (NASDAQ: NBSE)

    • On February 3rd, our sister organization, Tribe Public hosted a Webinar Presentation and Q&A Event titled “Drugging The Genome.” The event was co-hosted by Dietrich A. Stephan, Ph.D, CEO, & Founder of NeuBase Therapeutics (NASDAQ: NBSE). The event video may now be viewed at the Tribe Public YouTube Channel at this link
  •  
    • On Jan. 10, NeuBase announced  the appointment of Todd P. Branning as Chief Financial Officer (CFO). Mr. Branning has more than 25 years of experience leading corporate finance and accounting, tax, financial planning and analysis, and investor relations for several publicly traded pharmaceutical companies. Prior to joining NeuBase, Mr. Branning was CFO of Phathom Pharmaceuticals, Inc., a publicly traded late clinical-stage biopharmaceutical company. Before that, he was Senior Vice President, CFO of Amneal Pharmaceuticals, Inc., a publicly traded pharmaceutical company, where he helped to build, leverage, and optimize infrastructure following the completion of a transformational merger. Prior to joining Amneal, he was Senior Vice President, CFO of the global generic medicines division at Teva Pharmaceutical Industries Ltd., a multinational generic pharmaceuticals company, where he led the finance function and served on the leadership team responsible for managing the day-to-day operations of Teva’s largest multi-billion-dollar commercial unit. Mr. Branning has also held financial leadership roles at Allergan plc, PricewaterhouseCoopers LLP, PPG Industries, Inc., and Merck & Co., Inc. Mr. Branning received his BBA from the University of Miami and MBA from Carnegie Mellon University. Mr. Branning is also a Certified Public Accountant and has completed a CFO certification program at The Wharton School at the University of Pennsylvania.
    • On Jan. 5, Neubase announced the appointment of Eric J. Ende, M.D., to the Company’s Board of Directors. Dr. Ende has nearly 25 years of experience in advising biotechnology and life sciences companies to optimize corporate strategy and structure and maximize shareholder value. “Dr. Ende has the experience and perspective to recognize the opportunity ahead for NeuBase as it plans for the clinical development of its potentially transformational new class of precision genetic medicines,” said Dietrich A. Stephan, Ph.D., Founder, CEO and Chairman of NeuBase. “We welcome Dr. Ende’s strategic insight as we begin to scale our therapeutic candidate pipeline from our new precision genetic medicines platform technology. In addition to his broad experience, he also shares in our Company’s goal of helping millions of patients with both common and rare conditions that currently have limited or no treatment options.” “I believe NeuBase has a game-changing technology that overcomes the limitations of early precision genetic medicines by delivering mutation selectivity, repeat dosing, and systemic administration in a modular precision medicine platform with the potential to efficiently scale to treat a wide variety of diseases that are currently undruggable,” said Dr. Ende. “I look forward to working closely with NeuBase’s leadership team and Board of Directors to elevate strategy and operations in order to create exceptional value for patients and shareholders.” Dr. Ende currently is the President of Ende BioMedical Consulting Group. He also is a member of the Board of Directors of Matinas BioPharma, where he is the Chairman of the Compensation Committee and serves on the Audit and the Nomination & Governance Committees, and of Avadel plc, where he is the Chairman of the Nomination & Corporate Governance Committee and serves on the Audit and Compensation Committees. Dr. Ende previously served on the Board of Directors of Progenics (acquired by Lantheus Holdings) and Genzyme (acquired by Sanofi-Aventis for $20 billion). During his time on Genzyme’s Board of Directors, Dr. Ende was a member of the Audit and Risk Management Committees. Prior to Genzyme, Dr. Ende was a biotechnology analyst, previously serving at Merrill Lynch, BofA Securities, and Lehman Brothers. Dr. Ende received an M.B.A. from NYU Stern School of Business, an M.D. from the Icahn School of Medicine at Mount Sinai, and a B.S. in biology and psychology from Emory University.
  •  


Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates and let’s find ways to crush it again this year!

Investing & Inspiration

 

  1. Attitude determines the altitude of life.” – Edwin Louis Cole
  2. “Don’t go through life, grow through life.” – Eric Butterworth
  3. “Life is too short for long-term grudges.” – Elon Musk
  4. There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
  5. “Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
  6. “The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
  7. “Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
  8. “Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
  9. “But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
  10. “Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
  11. “Let there be work, bread, water and salt for all.” – Nelson Mandela
  12. “The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
  13. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  14. I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones. – Albert Einstein
  15. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  16. “If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
  17. “Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
  18. “Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
  19. Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
  20. “You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
  21. “Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
  22. “Delete the negative; accentuate the positive!” – Donna Karan
  23. “It’s crazy how fast time flies and how things progress.” – Nathan Chen
  24. The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
  25. “Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
  26. “Everything has beauty, but not everyone sees it.” – Confucius
  27. A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
  28. “Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
  29. “A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
  30. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  31. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  32. “I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox

  33. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn

  34. “But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye

  35. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  36. “Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
  37. No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
  38. “Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
  39. “Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
  40. “Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
  41. If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  42. “Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
  43. “The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
  44. “There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
  45. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  46. There is little that can withstand a man who can conquer himself.” – Louis XIV
  47. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  48. “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
  49. “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
  50. “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius
  51. “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
  52. “Never do anything against conscience even if the state demands it.”– Albert Einstein
  53. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  54. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
  55. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  56. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  57. “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
  58. “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
  59. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
  60. “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
  61. “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch
  62. “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
  63. “The secret of getting ahead is getting started.” – Mark Twain
  64. “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe
  65. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
  66. “If a man does not keep pace with his companions, perhaps it is because he hears a different drummer. Let him step to the music which he hears, however measured or far away.” – Henry David Thoreau
  67. “Adopting the right attitude can convert a negative stress into a positive one.” – Hans Selye
  68. “Money is something that keeps you alive and healthy and just keeps you focused. It’s the drive. It’s the passion.” – Travis Scott
  69. “Common sense is the collection of prejudices acquired by age eighteen.” – Albert Einstein
  70. “Live life to the fullest, and focus on the positive.” – Matt Cameron
  71. “You cannot escape the responsibility of tomorrow by evading it today.” – Abraham Lincoln
  72. “However difficult life may seem, there is always something you can do and succeed at.”– Stephen Hawking
  73. “Once you bring life into the world, you must protect it. We must protect it by changing the world.” – Elie Wiesel
  74. “Don’t let your ego get too close to your position, so that if your position gets shot down, your ego doesn’t go with it.” – Colin Powell
  75. “Good things do not come easy. The road is lined with pitfalls.” – Desi Arnaz
  76. Honoring the sacrifices many have made for our country in the name of freedom and democracy is the very foundation of Veterans Day.” – Charles B. Rangel,
  77. “The true sign of intelligence is not knowledge but imagination.” – Albert Einstein
  78. “Trust yourself, you know more than you think you do.” – Benjamin Spock
  79. “This idea of mutual appreciation and partnerships and investment in our people is very important to me and will continue to be important.” – Dennis Muilenburg
  80. “The true secret of happiness lies in taking a genuine interest in all the details of daily life.” – William Morris
  81. “Formal education will make you a living; self-education will make you a fortune.” – Jim Rohn
  82. “Give me the luxuries of life and I will willingly do without the necessities.” – Frank Lloyd Wright
  83. “If opportunity doesn’t knock, build a door.” – Milton Berle
  84. “Age is an issue of mind over matter. If you don’t mind, it doesn’t matter.” – Mark Twain
  85. “The smallest deed is better than the greatest intention.” – John Burroughs
  86. “It’s the steady, quiet, plodding ones who win in the lifelong race.” – Robert W. Service
  87. “When I was young I thought that money was the most important thing in life; now that I am old I know that it is.” – Oscar Wilde
  88. “A savvy entrepreneur will not always look for investment money, first.” – Daymond John
  89. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  90. “Look deep into nature, and then you will understand everything better.” -Albert Einstein

  91. “The young man knows the rules, but the old man knows the exceptions.” – Oliver Wendell Holmes, Sr.

  92. “Don’t go through life, grow through life.”– Eric Butterworth
  93. “This life is worth living, we can say, since it is what we make it.” – William James
  94. “People who think they know everything are a great annoyance to those of us who do.” –  Isaac Asimov
  95. “True life is lived when tiny changes occur.”  – Leo Tolstoy
  96. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  97. “In order to attain the impossible, one must attempt the absurd.” – Miguel de Cervantes
  98. “Aim for the moon. If you miss, you may hit a star.” – W. Clement Stone
  99. “If I had to live my life again, I’d make the same mistakes, only sooner.” – Tallulah Bankhead
  100. “The deal machinations many companies put themselves through, while certainly a bonanza for investment bankers, can confound the typical investor.” – Whitney Tilson
  101. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  102. “Procrastination is the art of keeping up with yesterday.” – Don Marquis
  103. “Do not fear mistakes. You will know failure. Continue to reach out.” – Benjamin Franklin

  104. “Success is peace of mind which is a direct result of self-satisfaction in knowing you did your best to become the best you are capable of becoming.” – John Wooden
  105. “One fails forward toward success.” – Charles Kettering
  106. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  107. “I hear and I forget. I see and I remember. I do and I understand.” – Confucius
  108. “I’m a very strong believer in listening and learning from others.” – Ruth Bader Ginsburg
  109. “Blessed are those who give without remembering and take without forgetting.” – Elizabeth Bibesco
  110. “As you walk down the fairway of life you must smell the roses, for you only get to play one round.” – Ben Hogan
  111. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  112. “Economics is all about consumption. People either spend money now or they use financial instruments – like bonds, stocks and savings accounts – so they can spend more later.” – Adam Davidson
  113. “Ever tried. Ever failed. No matter. Try Again. Fail again. Fail better.” -Samuel Beckett
  114. “In the post-industrial economy, ideas and great minds often provide far greater return on investment than any other resources or capital investments.” – Marvin Ammori
  115. “Work like you don’t need the money. Love like you’ve never been hurt. Dance like nobody’s watching.” – Satchel Paige
  116. “One of the rules I’ve learned is that struggling to try and think your way into making an investment is usually the best way to not have a great outcome.” – Stephen A. Schwarzman
  117. “The secret of business is to know something that nobody else knows.” – Aristotle Onassis
  118. “It takes a long time to grow an old friend.” – John Leonard
  119. “Life is a dream for the wise, a game for the fool, a comedy for the rich, a tragedy for the poor.”– Sholom Aleichem
  120. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  121. “Man is only great when he acts from passion.” – Benjamin Disraeli
  122. “We need to stop thinking about infrastructure as an economic stimulant and start thinking about it as a strategy. Economic stimulants produce Bridges to Nowhere. Strategic investment in infrastructure produces a foundation for long-term growth.” – Roger McNamee
  123. “We must let go of the life we have planned, so as to accept the one that is waiting for us.” – Joseph Campbell
  124. “Put your heart, mind, and soul into even your smallest acts. This is the secret of success.” – Swami Sivananda
  125. “I can’t change the direction of the wind, but I can adjust my sails to always reach my destination.” – Jimmy Dean
  126. “Companies have too many experts who block innovation. True innovation really comes from perpendicular thinking.” – Peter Diamandis
  127. “By failing to prepare, you are preparing to fail.” – Benjamin Franklin
  128. “We cannot solve our problems with the same thinking we used when we created them.” – Albert Einstein
  129. “When you’re an investor, you can look at the quantitative and qualitative elements of an investment, but there’s a third aspect: What you feel in your gut.” – Kevin O’Leary
  130. “Set your course by the stars, not by the lights of every passing ship.” – Omar N. Bradley
  131. “Do not take life too seriously. You will never get out of it alive.” – Elbert Hubbard
  132. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey 
  133. “Every good painter paints what he is.” – Jackson Pollock
  134. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  135. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  136. “You cannot have a positive life and a negative mind.” – Joyce Meyer 
  137. “Like wildebeest and zebra migration across the Serengeti, investment managers and consultants, too, have a habit of running together and, every now and then, changing direction.” – Sanjaya Baru
  138. “If people are anything but enthusiastic about the information or ideas that they’re sharing, they’re either not that invested in what they’re doing – or they’re not communicating that investment effectively.” – Ana Kasparian 
  139. “Life consists not in holding good cards but in playing those you hold well.” – Josh Billings 
  140. “Friend, there’s no greater investment in life than in being a people builder. Relationships are more important than our accomplishments.” – Joel Osteen
  141. “It’s only natural that the heavy users help contribute to the investment to keep the Web healthy. That is the most important concept of net neutrality.” – Lowell McAdam
  142. “The more sand that has escaped from the hourglass of our life, the clearer we should see through it.” – Jean Paul 
  143. “Eliminate emotion from your investment program.” -John C. Bogle

  144. “Modern medical advances have helped millions of people live longer, healthier lives. We owe these improvements to decades of investment in medical research.” – Ike Skelton
  145. “In every investment, before I get involved or invest, I always see what the mindset of the founder, the CEO, is.” – Zaza Pachulia
  146. “An investment said to have an 80% chance of success sounds far more attractive than one with a 20% chance of failure. The mind can’t easily recognize that they are the same.” – Daniel Kahneman
  147. “The return on investment in global health is tremendous, and the biggest bang for the buck comes from vaccines. Vaccines are among the most successful and cost-effective health investments in history.” – Seth Berkley
  148. “Few things in the world are more powerful than a positive push. A smile. A world of optimism and hope. A ‘you can do it’ when things are tough.” – Richard M. DeVos
  149. “To be yourself in a world that is constantly trying to make you something else is the greatest accomplishment.” – Ralph Waldo Emerson
  150. “We all have dreams. But in order to make dreams come into reality, it takes an awful lot of determination, dedication, self-discipline, and effort.”  – Jesse Owens
  151. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward- American Writer, Born 1921
  152. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  153. “The secret of your future is hidden in your daily routine.” – Mike Murdock
  154.  “If somebody puts you down or criticizes you, just keep on believing in yourself and turn it into something positive.” – Leah LaBelle
  155. “Opportunity is missed by most people because it is dressed in overalls and looks like work”. -Thomas A. Edison
  156. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  157. “Human behavior flows from three main sources: desire, emotion, and knowledge.” – Plato

  158. “We are what our thoughts have made us; so take care about what you think. Words are secondary. Thoughts live; they travel far.” – Swami Vivekananda
  159. “Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
  160. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll

  161. “Don’t worry about being a star, worry about doing good work, and all that will come to you.” – Ice Cube

  162. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare

  163. Prediction is very difficult, especially if it’s about the future.” – Niels Bohr (Danish Physicist)
  164. “It is indeed true that the stock market can forecast the business cycle.” -Paul Samuelson

  165. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sacks

  166. “What lies behind you and what lies in front of you, pales in comparison to what lies inside of you.” – Ralph Waldo Emerson
  167. “Each new generation born is in effect an invasion of civilization by little barbarians, who must be civilized before it is too late.” – Thomas Sowell
  168. “Life is 10% what happens to you and 90% how you react to it.” – Charles R. Swindoll
  169. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  170. “View health as an investment, not an expense.” – John Quelch

  171. “Opportunity does not knock, it presents itself when you beat down the door.” – Kyle Chandler

  172. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll
  173. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  174. “That which does not kill us makes us stronger.” – Friedrich Nietzsche
  175. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  176. “A problem is a chance for you to do your best.”–  Duke Ellington
  177. “The best way to predict the future is to create it.” -Peter Drucker
  178. “I’m involved in the stock market, which is fun and, sometimes, very painful.” – Regis Philbin
  179. “Who owns the future? This is the question at the heart of every stock market.” – John Landgraf
  180. “One of the funny things about the stock market is that every time one person buys, another sells, and both think they are astute.” – William Feather
  181. While I’m sure some millennials are concerned with the ethical issues involved in mining for diamonds, the main reason they steer clear of the gems is because, well, they’re a dumb investment.” – Ana Kasparian
  182. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sack
  183. “We must shift our thinking away from short-term gain toward long-term investment and sustainability, and always have the next generations in mind with every decision we make.” –  Deb Haaland
  184. “The only way to have a friend is to be one.” –  Ralph Waldo Emerson
  185. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  186. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” -Liya Kebede

  187. “Success is not final, failure is not fatal: it is the courage to continue that counts.”– Winston Churchill
  188. “Our greatest glory is not in never falling, but in rising every time we fall.” – Confucius

  189. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes
  190. “Who controls the past controls the future. Who controls the present controls the past.” – George Orwell
  191. “If you get up in the morning and think the future is going to be better, it is a bright day. Otherwise, it’s not.” – Elon Musk
  192. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward
  193. “Start where you are. Use what you have. Do what you can.” – Arthur Ashe
  194. “Netflix, Amazon, iTunes – whatever platforms emerge – we are looking at as having the same potential that home video had for the movie business. Which means there are entirely new opportunities to monetize our capital investment in content and do so in ways that work for distributors, for consumers and for creators.” – Bob Iger
  195. “When you have no one to answer to, vendetta as investment strategy is as legitimate as anything.” – Carl Icahn

  196. “No other investment yields as great a return as the investment in education. An educated workforce is the foundation of every community and the future of every economy.” – Brad Henry
  197. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  198. “Modern medical advances have helped millions of people live longer, healthier lives.

  199. We owe these improvements to decades of investment in medical research.”– Ike Skelton

  200. “Stock market goes up or down, and you can’t adjust your portfolio based on the whims of the market, so you have to have a strategy in a position and stay true to that strategy and not pay attention to noise that could surround any particular investment.” – John Paulson

  201. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  202. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  203. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  204. “I think you have to learn that there’s a company behind every stock and there’s only one real reason why stocks go up. Companies go from doing poorly to doing well or small companies grow to large companies.” – Peter Lynch
  205. “Historically, there has been a bull market in the commodities every 20 or 30 years.” – Jim Rogers
  206. “The markets generally are unpredictable, so that one has to have different scenarios. The idea that you can actually predict what’s going to happen contradicts my way of looking at the market.” – George Soros
  207. “Stop trying to predict the direction of the stock market, the economy or the elections.” – Warren Buffett
  208. “An important key to investing is to remember that stocks are not lottery tickets.” – Peter Lynch
  209. “Learn everyday, but especially from the experiences of others. It’s cheaper!” – John Bogle
  210. “When purchasing depressed stock in troubled companies, seek out the ones with the superior financial positions and avoid the ones with loads of bank debt.” – Peter Lynch
  211. “No stock price is too low for bears or too high for bulls.” – John F. Heerdink, Jr.
  212. “Investment is most successful when it is most businesslike.” – Ben Graham

  213. “Value stocks are about as exciting as watching grass grow, but have you ever noticed just how much your grass grows in a week?” – Christopher Browne

  214. “Even the intelligent investor is likely to need considerable willpower to keep from following the crowd.” – Benjamin Graham
  215. “Individual who cannot master their emotions are ill-suited to profit from the investment process.” – Benjamin Graham
  216. “I made my first investment at age eleven. I was wasting my life until then.” – Warren Buffet
  217. “I don’t look to jump over seven-foot bars; I look around for one-foot bars that I can step over.” — Warren Buffett
  218. “There are only three measurements that tell you nearly everything you need to know about your organization’s overall performance: employee engagement, customer satisfaction, and cash flow. It goes without saying that no company, small or large, can win over the long run without energized employees who believe in the mission and understand how to achieve it.” – Jack Welch, former CEO of GE
  219. “Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble” ― Warren Buffett
  220. “If you buy things you do not need, soon you will have to sell things you need.” – Warren Buffet
  221. “How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.” — Robert G. Allen
  222. “It’s far better to buy a wonderful company at a fair price, than a fair company at a wonderful price.” – Warren Buffett
  223. “A market downturn doesn’t bother us. It is an opportunity to increase our ownership of great companies with great management at good prices.” — Warren Buffett
  224. “Every once in a while, the market does something so stupid it takes your breath away.” — Jim Cramer
  225. “The person who starts simply with the idea of getting rich won’t succeed; you must have a larger ambition.” — John D. Rockefeller
  226. “Know what you own, and know why you own it.” – Peter Lynch
  227. “Although it’s easy to forget sometimes, a share is not a lottery ticket… it’s part ownership of a business.” – Peter Lynch
  228. “Wise spending is part of wise investing. And it’s never too late to start.” – Rhonda Katz
  229. “Invest for the long haul. Don’t get too greedy and don’t get too scared.” – Shelby M.C. Davis

  230. “Fear incites human action far more urgently than does the impressive weight of historical evidence.”
    -Jeremy Siegel
  231. “With a good perspective on history, we can have a better understanding of the past and present, and thus a clear vision of the future.” — Carlos Slim Helu
  232. “If we like a business, we’re going to buy as much of it as we can and keep it as long as we can. And when we change our mind, we don’t take half measures.” – Warren Buffett
  233. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel

  234. “Never depend on a single income, make an investment to create a second source.” Warren Buffet

  235. Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.”
    ― Warren Buffett
  236. “The key to making money in stocks is not to get scared out of them.” – Peter Lynch
  237. “Courage taught me no matter how bad a crisis gets … any sound investment will eventually pay off.” — Carlos Slim Helu
  238. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  239. “As time goes on, I get more and more convinced that the right method of investment is to put fairly large sums into enterprises which one thinks one knows something about and in the management of which one thoroughly believes.” — John Maynard Keynes
  240. “Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos
  241. “Money is always eager and ready to work for anyone who is ready to employ it.” ― Idowu Koyenikan
  242. The secret to investing is to figure out the value of something – and then pay a lot less.” – Joel Greenblatt
  243. “We don’t have an analytical advantage, we just look in the right place.” – Seth Klarman
  244. “Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
  245. “It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
  246. “No Price is too low for a bear or too high for a bull.” — Anonymous
  247. “Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” Anonymous
  248. “Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
  249. “Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
  250. “It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
  251. “A bull market is like sex. It feels best just before it ends.” — Barton Biggs
  252. “The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
  253. “No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
  254. “Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
  255. “Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
  256. “Never count on making a good sale. Have the purchase price be so attractive that even a mediocre sale gives good results” — Warren Buffett
  257. “The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
  258. “Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
  259. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  260. “You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr. 
  261. “Know what you own, and know why you own it.” – Peter Lynch
  262. “Liquidity is only there when you don’t need it.” -Old Proverb
  263. “If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
  264. “Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
  265. “In investing, what is comfortable is rarely profitable.” – Robert Arnott
  266. “Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
  267. “The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
  268. “The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – Pope Francis
  269. “It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
  270. “An investment in knowledge pays the best interest.” – Benjamin Franklin.
  271. I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
  272. “Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
  273. “The tax on capital gains directly affects investment decisions, the mobility, and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
  274. “If all the economists were laid end to end, they’d never reach a conclusion. -George Bernard Shaw
  275. “There are old traders and there are bold traders, but there are very few old, bold traders.”-Ed Seykota
  276. “Let this scenario play out on its own, in its own fashion. As you watch it unfold, you will soon be grateful that you choose the peaceful path. Remember — those who live by the sword, die by the sword.”
  277. “As long as you enjoy investing, you’ll be willing to do the homework and stay in the game.” -Jim Cramer
  278. “I rarely think the market is right. I believe non-dividend stocks aren’t much more than baseball cards. They are worth what you can convince someone to pay for it.” -Mark Cuban
  279. Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
  280. “The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
  281. “The only true test of whether a stock is “cheap” or “high” is not its current price in relation to some former price, no matter how accustomed we may have become to that former price, but whether the company’s fundamentals are significantly more or less favorable than the current financial-community appraisal of that stock.” -Philip Fisher
  282. “I learned to avoid trying to catch up or double up to recoup losses. I also learned that a certain amount of loss will affect your judgment, so you have to put some time between that loss and the next trade.” -Richard Dennis
  283. “The four most dangerous words in investing are: ‘this time it’s different.” -Sir John Templeton
  284. “Money doesn’t make you happy. I now have $50 million but I was just as happy when I had $48 million.” -Arnold Schwarzenegger

Videos

Please consider viewing these interesting videos: